Our TEPI patch technology may also be suitable for the life-cycle management of existing products by providing a new route of delivery with patent protection. For instance, when a product is approaching the end of its cycle, switching to patch delivery could prolong its life.
Medherant also offers low-cost feasibility studies for NCEs that could benefit from transdermal delivery due to GI toxicity or first-pass metabolism associated with other delivery methods.
It is also important to note that the adhesive does not requre any solvent; drugs and excipients dissolve directly in the polymer matrix prior to curing with water. This makes for cheaper, environmentally friendly manufacturing.
Contact us to find out more.